Elizabeth C Oelsner1, Pallavi P Balte1, Morgan E Grams2, Patricia A Cassano3, David R Jacobs4, R Graham Barr1, Kristin M Burkart1, Ravi Kalhan5, Richard Kronmal6, Laura R Loehr7, George T O'Connor8, Joseph E Schwartz1,9, Michael Shlipak10, Russell P Tracy11, Michael Y Tsai12, Wendy White13, Sachin Yende14,15. 1. 1 Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York. 2. 2 Department of Medicine, Johns Hopkins University, Baltimore, Maryland. 3. 3 Division of Nutritional Sciences, College of Human Ecology, Cornell University, Cornell, New York. 4. 4 Division of Epidemiology and Community Health and. 5. 5 Department of Medicine, Northwestern University, Chicago, Illinois. 6. 6 Department of Statistics, School of Public Health, University of Washington, Seattle, Washington. 7. 7 Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina. 8. 8 Department of Medicine, Boston University, Boston, Massachusetts. 9. 9 Department of Psychiatry and Behavioral Sciences, Stony Brook University, Stony Brook, New York. 10. 10 Department of Medicine, University of California, San Francisco, San Francisco, California. 11. 11 Laboratory for Clinical Biochemistry Research, University of Vermont, Burlington, Vermont. 12. 12 Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota. 13. 13 Jackson Heart Study, Undergraduate Training and Education Center, Tougaloo College, Jackson, Mississippi; and. 14. 14 Veterans Affairs Pittsburgh Healthcare System and. 15. 15 Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
RATIONALE: Chronic lower respiratory diseases (CLRDs), including chronic obstructive pulmonary disease (COPD) and asthma, are the fourth leading cause of death. Prior studies suggest that albuminuria, a biomarker of endothelial injury, is increased in patients with COPD. OBJECTIVES: To test whether albuminuria was associated with lung function decline and incident CLRDs. METHODS: Six U.S. population-based cohorts were harmonized and pooled. Participants with prevalent clinical lung disease were excluded. Albuminuria (urine albumin-to-creatinine ratio) was measured in spot samples. Lung function was assessed by spirometry. Incident CLRD-related hospitalizations and deaths were classified via adjudication and/or administrative criteria. Mixed and proportional hazards models were used to test individual-level associations adjusted for age, height, weight, sex, race/ethnicity, education, birth year, cohort, smoking status, pack-years of smoking, renal function, hypertension, diabetes, and medications. MEASUREMENTS AND MAIN RESULTS: Among 10,961 participants with preserved lung function, mean age at albuminuria measurement was 60 years, 51% were never-smokers, median albuminuria was 5.6 mg/g, and mean FEV1 decline was 31.5 ml/yr. For each SD increase in log-transformed albuminuria, there was 2.81% greater FEV1 decline (95% confidence interval [CI], 0.86-4.76%; P = 0.0047), 11.02% greater FEV1/FVC decline (95% CI, 4.43-17.62%; P = 0.0011), and 15% increased hazard of incident spirometry-defined moderate-to-severe COPD (95% CI, 2-31%, P = 0.0021). Each SD log-transformed albuminuria increased hazards of incident COPD-related hospitalization/mortality by 26% (95% CI, 18-34%, P < 0.0001) among 14,213 participants followed for events. Asthma events were not significantly associated. Associations persisted in participants without current smoking, diabetes, hypertension, or cardiovascular disease. CONCLUSIONS: Albuminuria was associated with greater lung function decline, incident spirometry-defined COPD, and incident COPD-related events in a U.S. population-based sample.
RATIONALE: Chronic lower respiratory diseases (CLRDs), including chronic obstructive pulmonary disease (COPD) and asthma, are the fourth leading cause of death. Prior studies suggest that albuminuria, a biomarker of endothelial injury, is increased in patients with COPD. OBJECTIVES: To test whether albuminuria was associated with lung function decline and incident CLRDs. METHODS: Six U.S. population-based cohorts were harmonized and pooled. Participants with prevalent clinical lung disease were excluded. Albuminuria (urine albumin-to-creatinine ratio) was measured in spot samples. Lung function was assessed by spirometry. Incident CLRD-related hospitalizations and deaths were classified via adjudication and/or administrative criteria. Mixed and proportional hazards models were used to test individual-level associations adjusted for age, height, weight, sex, race/ethnicity, education, birth year, cohort, smoking status, pack-years of smoking, renal function, hypertension, diabetes, and medications. MEASUREMENTS AND MAIN RESULTS: Among 10,961 participants with preserved lung function, mean age at albuminuria measurement was 60 years, 51% were never-smokers, median albuminuria was 5.6 mg/g, and mean FEV1 decline was 31.5 ml/yr. For each SD increase in log-transformed albuminuria, there was 2.81% greater FEV1 decline (95% confidence interval [CI], 0.86-4.76%; P = 0.0047), 11.02% greater FEV1/FVC decline (95% CI, 4.43-17.62%; P = 0.0011), and 15% increased hazard of incident spirometry-defined moderate-to-severe COPD (95% CI, 2-31%, P = 0.0021). Each SD log-transformed albuminuria increased hazards of incident COPD-related hospitalization/mortality by 26% (95% CI, 18-34%, P < 0.0001) among 14,213 participants followed for events. Asthma events were not significantly associated. Associations persisted in participants without current smoking, diabetes, hypertension, or cardiovascular disease. CONCLUSIONS: Albuminuria was associated with greater lung function decline, incident spirometry-defined COPD, and incident COPD-related events in a U.S. population-based sample.
Authors: B H Goodpaster; C L Carlson; M Visser; D E Kelley; A Scherzinger; T B Harris; E Stamm; A B Newman Journal: J Appl Physiol (1985) Date: 2001-06
Authors: M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger Journal: Eur Respir J Date: 2005-08 Impact factor: 16.671
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: Gary L Myers; W Greg Miller; Josef Coresh; James Fleming; Neil Greenberg; Tom Greene; Thomas Hostetter; Andrew S Levey; Mauro Panteghini; Michael Welch; John H Eckfeldt Journal: Clin Chem Date: 2005-12-06 Impact factor: 8.327
Authors: Ciro Casanova; Juan P de Torres; Juan Navarro; Armando Aguirre-Jaíme; Pablo Toledo; Elizabeth Cordoba; Rebeca Baz; Bartolomé R Celli Journal: Am J Respir Crit Care Med Date: 2010-06-17 Impact factor: 21.405
Authors: E C Oelsner; T D Pottinger; K M Burkart; M Allison; S G Buxbaum; N N Hansel; R Kumar; E K Larkin; L A Lange; L R Loehr; S J London; G T O'Connor; G Papanicolaou; M F Petrini; D Rabinowitz; S Raghavan; S Redline; B Thyagarajan; R P Tracy; J B Wilk; W B White; S S Rich; R G Barr Journal: Biomarkers Date: 2013-04-05 Impact factor: 2.658
Authors: G D Friedman; G R Cutter; R P Donahue; G H Hughes; S B Hulley; D R Jacobs; K Liu; P J Savage Journal: J Clin Epidemiol Date: 1988 Impact factor: 6.437
Authors: Joshua I Barzilay; Petra Buzkova; Michael G Shlipak; Nisha Bansal; Pranav Garimella; Kenneth J Mukamal Journal: J Gerontol A Biol Sci Med Sci Date: 2020-11-13 Impact factor: 6.053
Authors: Pallavi P Balte; Paulo H M Chaves; David J Couper; Paul Enright; David R Jacobs; Ravi Kalhan; Richard A Kronmal; Laura R Loehr; Stephanie J London; Anne B Newman; George T O'Connor; Joseph E Schwartz; Benjamin M Smith; Lewis J Smith; Wendy B White; Sachin Yende; Elizabeth C Oelsner Journal: JAMA Intern Med Date: 2020-05-01 Impact factor: 21.873
Authors: William Z Zhang; Michelle C Rice; Katherine L Hoffman; Clara Oromendia; Igor Z Barjaktarevic; J Michael Wells; Annette T Hastie; Wassim W Labaki; Christopher B Cooper; Alejandro P Comellas; Gerard J Criner; Jerry A Krishnan; Robert Paine; Nadia N Hansel; Russell P Bowler; R Graham Barr; Stephen P Peters; Prescott G Woodruff; Jeffrey L Curtis; Meilan K Han; Karla V Ballman; Fernando J Martinez; Augustine Mk Choi; Kiichi Nakahira; Suzanne M Cloonan; Mary E Choi Journal: JCI Insight Date: 2020-02-13
Authors: Elizabeth C Oelsner; Pallavi P Balte; Surya P Bhatt; Patricia A Cassano; David Couper; Aaron R Folsom; Neal D Freedman; David R Jacobs; Ravi Kalhan; Amanda R Mathew; Richard A Kronmal; Laura R Loehr; Stephanie J London; Anne B Newman; George T O'Connor; Joseph E Schwartz; Lewis J Smith; Wendy B White; Sachin Yende Journal: Lancet Respir Med Date: 2019-10-09 Impact factor: 102.642
Authors: Angelico Mendy; Päivi M Salo; Jesse Wilkerson; Lydia Feinstein; Michael B Fessler; Peter S Thorne; Darryl C Zeldin Journal: Ann Am Thorac Soc Date: 2021-12
Authors: Lucilla Piccari; Roberto Del Pozo; Isabel Blanco; Jessica García-Lucio; Yolanda Torralba; Olga Tura-Ceide; Jorge Moises; Marta Sitges; Víctor Ivo Peinado; Joan Albert Barberà Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-08-26
Authors: Anouk W Vaes; Martijn A Spruit; Karel Van Keer; João Barbosa-Breda; Emiel F M Wouters; Frits M E Franssen; Jan Theunis; Patrick De Boever Journal: Sci Rep Date: 2020-01-08 Impact factor: 4.379